EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer

Kimberly Luddy, Hannah Newman, Jordan Gravon, Mark Robertson-Tessi, Robert Gatenby

PET Clinics · 2026

DOI: 10.1016/j.cpet.2025.08.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2026. Verfasst von Kimberly Luddy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunotherapy, Radiopharmaceuticals. Die Arbeit nennt 80 Literaturangaben. Gefördert von: National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review highlights the critical role of evolutionary dynamics in metastatic prostate cancer treatment. It emphasizes that resistance arises through Darwinian selection, often driven by continuous maximum tolerated dose therapies. Evolution-informed strategies, such as adaptive therapy and exploiting collateral sensitivities, aim to delay resistance and prolong disease control by steering tumor evolution. Radiopharmaceutical therapy, especially when combined with immunotherapy, offers promising avenues for targeting disseminated tumors. Integrating mathematical models and computer simulations to understand tumor evolution can optimize personalized, adaptive treatment regimens, transforming resistance from a failure into an exploitable vulnerability, ultimately improving outcomes in advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsImmunotherapyRadiopharmaceuticalsHumansMaleComputer SimulationNeoplasm MetastasisCombined Modality Therapy

Stichwörter der Autor:innen

Cancer evolutionImmunotherapyProstate cancerRadiopharmaceutical therapyTheranosticsevolutionary double bind

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Immunology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
  • Department of Integrated Mathematical Oncology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
  • Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
  • Department of Radiology, Cancer Biology and Evolution Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address: Robert.gatenby@moffitt.org.

Förderung

  • National Institutes of Health National Cancer Institute

Zitieren

APA

Luddy, K., Newman, H., Gravon, J., Robertson-Tessi, M., & Gatenby, R. (2026). Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clinics. https://doi.org/10.1016/j.cpet.2025.08.006

Vancouver

Luddy K, Newman H, Gravon J, Robertson-Tessi M, Gatenby R. Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clinics. 2026. doi:10.1016/j.cpet.2025.08.006

BibTeX
@article{Luddy2026,
  author = {Luddy, Kimberly and Newman, Hannah and Gravon, Jordan and Robertson-Tessi, Mark and Gatenby, Robert},
  title = {Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer},
  journal = {PET Clinics},
  year = {2026},
  doi = {10.1016/j.cpet.2025.08.006}
}
Kostenlos starten →